IDEAYA Biosciences (IDYA) EBT Margin (2020 - 2026)

IDEAYA Biosciences has disclosed EBT Margin across 7 years of filings, most recently posting 1654.63% for Q1 2026.

• EBT Margin for Q1 2026 came in at 1654.63%, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was 78.99% (changed N/A YoY), and the FY2025 annual result was 72.84%, up 459823.0% from the prior year.
• EBT Margin came in at 1654.63% for Q1 2026 at IDEAYA Biosciences, down from 869.53% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 52.18% in Q3 2025 to a low of 2059.11% in Q4 2024.
• The 5-year median for EBT Margin is 537.28% (2022), against an average of 703.2%.
• Across the five-year window, EBT Margin slumped 99035 bps in 2024 and surged 118959 bps in 2025, its largest moves.
• IDEAYA Biosciences' EBT Margin stood at 657.46% in 2022, then plunged by 63 bps to 1068.77% in 2023, then sank by 93 bps to 2059.11% in 2024, then soared by 58 bps to 869.53% in 2025, then slumped by 90 bps to 1654.63% in 2026.
• The last three EBT Margin figures came in at 1654.63% (Q1 2026), 869.53% (Q4 2025), and 52.18% (Q3 2025), per Business Quant data.